Treatment effect relative to Abatacept + MTX | Difference in mean HAQ CFB at 24/26 weeks (95% CrL)* | Difference in mean HAQ CFB at 48/54 weeks (95% CrL)** | OR for ACR-50 at 24/26 weeks (95% CrL)* | OR for ACR-50 at 48/54 weeks (95% CrL)** | OR for DAS28 < 2.6 at 24/26 weeks (95% CrL)* | OR for DAS28 < 2.6 at 48/54 weeks (95% CrL)* |
---|---|---|---|---|---|---|
Placebo + MTX | -0.30 (-0.41; -0.18) | -0.29 (-0.38; -0.21) | 3.37 (1.49; 8.06) | 3.84 (2.84; 5.26) | 4.77 (1.60; 15.78) | 8.82 (1.50; 57.83) |
Adalimumab + MTX | 0.03 (-0.16; 0.24) | 0.05 (-0.09; 0.18) | 0.40 (0.09; 1.50) | 0.56 (0.29; 1.03) | Â | Â |
Certolizumab Pegol + MTX | 0.08 (-0.09; 0.28) | 0.13 (-0.00; 0.26) | 0.35 (0.08; 1.33) | 0.51 (0.26; 0.96) | 0.26 (0.01; 3.90) | Â |
Etanercept + MTX | -0.02 (-0.24; 0.21) | 0.05 (-0.22; 0.32) | 1.05 (0.17; 3.24) | 0.72 (0.43; 1.19) | 1.69 (0.21; 15.80) | 2.94 (0.14; 67.12) |
Golimumab + MTX | 0.04 (-0.21; 0.30) | Â | 0.87 (0.16; 5.15) | Â | 1.18 (0.13; 11.66) | Â |
Infliximab + MTX | -0.11 (-0.29; 0.08) | -0.11 (-0.22; 0.01) | 1.31 (0.27; 7.61) | 1.40 (0.93; 2.10) | 0.88 (0.09; 7.76) | 1.68 (0.14; 21.23) |
Rituximab + MTX | -0.09 (-0.31; 0.14) | 0.01 (-0.34; 0.35) | 0.85 (0.20; 3.47) | 0.31 (0.04; 1.37) | Â | Â |
Tocilizumab + MTX | -0.09 (-0.35; 0.18) | Â | 0.51 (0.10; 2.88) | Â | 0.05 (0.00; 0.79) | Â |